Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced on 24 Oct 2025 that it presented new pre‑clinical data for its lead solid‑tumor candidate ATNM‑400 at the 32nd Annual Prostate Cancer Foundation Scientific Retreat, held in Carlsbad, CA from 23‑25 Oct 2025. The press release, dated 24 Oct 2025, highlighted the presentation of the data at the conference.
The data demonstrate that ATNM‑400, which targets a novel non‑PSMA antigen expressed after androgen‑receptor pathway inhibitor and 177Lu‑PSMA‑617 therapy, achieved superior efficacy over both 177Lu‑PSMA‑617 and 225Ac‑PSMA‑617 in low‑PSMA and treatment‑resistant prostate cancer models. Durable anti‑tumor responses were observed, exceeding those achieved with the AR‑pathway inhibitor enzalutamide, and combination of ATNM‑400 with enzalutamide produced complete tumor regression in 40 % of prostate‑cancer‑bearing animals.
This pre‑clinical breakthrough positions ATNM‑400 as a promising candidate for patients with treatment‑resistant prostate cancer and could expand Actinium’s addressable market beyond PSMA‑targeted therapies. The findings may accelerate the company’s clinical development timeline and enhance its competitive positioning in the growing targeted radiotherapy market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.